Author

S. Barnhoorn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

C. Dirven· 1 shared C. Payan· 1 shared C. Verheul· 1 shared C. Voskamp· 1 shared E. Struys· 1 shared G. v. Osch· 1 shared I. Ntafoulis· 1 shared L. Anderson· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

C. Dirven

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TWIST1 controls cellular senescence and energy metabolism in mesenchymal stem cells

C. Voskamp, L. Anderson, W. Koevoet, S. Barnhoorn, P. G. Mastroberardino, G. v. Osch, R. Narcisi

This study shows that TWIST1 regulates senescence and metabolism in human mesenchymal stem cells, with TWIST1 silencing inducing a distinct SASP and metabolic profile compared to irradiation-induced senescence.

European Cells and Materials · Nov 26, 2021Peer-reviewedCell Biology

Generation, characterization and drug sensitivities of twelve patient-derived IDH1 mutant glioma cell cultures

C. Verheul, I. Ntafoulis, T. Kers, Y. Hoogstrate, P. Mastroberardino, S. Barnhoorn, C. Payan, R. Tching Chi Yen, E. Struys, S. Koolen, C. Dirven, S. Leenstra, P. French, M. Lamfers

The paper establishes twelve patient-derived IDH1 mutant glioma cell cultures, confirms their similarity to parental tumors, and identifies nine FDA-approved drugs with activity against IDH-mutant gliomas.

bioRxiv · Apr 9, 2021 · PreprintCancer Biology